Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com

Kura Oncology (NASDAQ:KURA) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

Several other analysts also recently issued reports on the company. Bank of America decreased their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Trading Up 4.5 %

Shares of NASDAQ KURA opened at $7.70 on Friday. The business has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $13.51. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The stock has a market cap of $598.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC boosted its position in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares in the last quarter. Harbor Advisors LLC bought a new stake in Kura Oncology during the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the 4th quarter valued at $90,000. Corton Capital Inc. bought a new position in Kura Oncology in the 4th quarter valued at $99,000. Finally, Optimize Financial Inc acquired a new position in Kura Oncology in the fourth quarter worth $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.